The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2019 | CD19 and CD20 CAR T-cell therapy for non-Hodgkin lymphoma
Nirav Niranjan Shah, MD, of the Medical College of Wisconsin, Milwaukee, WI, discusses the first bispecific chimeric antigen receptor (CAR) T-cell trial for patients with relapsed/refractory B-cell non-Hodgkin lymphoma. Dr Shah tells us about the high response rates and complete remissions witnessed in patients treated in the Phase I trial (NCT03019055), which studied differing dose levels of CAR T-cell products that target both CD-19 and CD-20. This interview was recorded at the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.
